NextCure CEO Departs; Interim CEO Appointed
Ticker: NXTC · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
Related Tickers: NXTC
TL;DR
NextCure CEO Richman out, Burrill steps in as interim CEO and board member.
AI Summary
On June 18, 2024, NextCure, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced the departure of Dr. Michael J. Richman as Chief Executive Officer and President, effective June 17, 2024. Concurrently, the company appointed Dr. G. Steven Burrill as interim CEO and President, and also elected him to the Board of Directors. Additionally, the filing disclosed compensatory arrangements for these executive changes.
Why It Matters
This filing indicates a significant leadership change at NextCure, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- Dr. Michael J. Richman (person) — Departing CEO and President
- June 17, 2024 (date) — Effective date of CEO departure
- Dr. G. Steven Burrill (person) — Appointed interim CEO and President, and elected to Board of Directors
- June 18, 2024 (date) — Date of report
FAQ
Who has been appointed as the interim CEO and President of NextCure, Inc.?
Dr. G. Steven Burrill has been appointed as the interim CEO and President of NextCure, Inc.
When did Dr. Michael J. Richman's departure as CEO and President become effective?
Dr. Michael J. Richman's departure became effective on June 17, 2024.
In addition to interim CEO, what other role has Dr. G. Steven Burrill taken on?
Dr. G. Steven Burrill has also been elected to the Board of Directors.
What is the exact date of this 8-K filing?
The exact date of this 8-K filing is June 18, 2024.
What is the principal executive office address for NextCure, Inc.?
The principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
Filing Stats: 697 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-06-18 16:10:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NXTC Nasdaq Glo
Filing Documents
- nxtc-20240618x8k.htm (8-K) — 48KB
- nxtc-20240618xex10d1.htm (EX-10.1) — 63KB
- 0001558370-24-009282.txt ( ) — 256KB
- nxtc-20240618.xsd (EX-101.SCH) — 4KB
- nxtc-20240618_def.xml (EX-101.DEF) — 3KB
- nxtc-20240618_lab.xml (EX-101.LAB) — 17KB
- nxtc-20240618_pre.xml (EX-101.PRE) — 12KB
- nxtc-20240618x8k_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 10.1 Scientific Advisory and Consulting Agreement, executed as of June 18, 2024, by and between NextCure, Inc. and Dr. Han Myint, M.D. 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November Dated: June 18, 2024 NEXTCURE, INC. By: /s/ Steven P. Cobourn Name: Steven P. Cobourn Title: Chief Financial Officer